1Durak H, Soylev M, Durak I, et al. Tc-99m polyclonal human immunoglobulin G imaging in Graves' ophthalmopathy. Clin Nucl Med,2000,25: 704-707.
2Ortapamuk H, Hosal B, Naldoken S. The role of Tc-99m polyclonal human immunoglobulin G scintigraphy in Graves' ophthalmopathy. Ann Nucl Med, 2002,16:461-465.
3Kulig G, Pilarska K, Kulig J, et al. Usefulness of soluble ICAM-1 measurements for the evaluation of the disease activity and efficiency of therapy in patients with infiltrative Graves' ophthalmopathy. Pol Arch Med Wewn,2002,108:1161-1169.
4De Bellis A, Di Martino S, Fiordelisi F, et al. Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy. J Clin Endocrinol Metab, 1998,83:1222-1225.
5Mysliwiec J, Kretowski A, Szelachowska M, et al. Serum L-selectin and ICAM-1 in patients with Graves' ophthalmopathy during treatment with corticosteroids. Immunol Lett, 2001,78:123-126.
6Gunji K, De Bellis A, Li AW, et al. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab, 2000, 85: 1641-1647.
7De Bellis A, Bizzarro A, Conte M, et al. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy. Clin Endocrinol ( Oxf),2003,59: 388-395.
8Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med, 1998,338: 73-78.
9Marcocci C, Bruno-Bossio G, Manetti L, et al. The course of Graves'ophthalmopathy is not influenced by near total thyroidectomy: a casecontrol study. Clin Endocrinol (Oxf), 1999,51: 503 -508.
10Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspective. Endocr Rev, 2000,21:168-199.
